Mineralys Therapeutics Inc.

NASDAQ: MLYS
Share price (3/21/25): $16.87
Market cap (3/21/25): $841 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Registration of securities for employees

Prospectus supplement for primary offering

Ownership Filter

Samsara BioCapital, L.P.

Samsara BioCapital, L.P., Samsara BioCapital GP, LLC

Akkaraju Srinivas

Ra Capital Management, L.P.

RA Capital Healthcare Fund LP, Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., RA Capital Nexus Fund III, L.P.

News Filter

Announces Proposed Public Offering of Common Stock

Announces Positive Topline Results From Launch-Htn and Advance-Htn Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Completes Enrollment in Explore-Ckd Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects With Stage 2 to 3b CKD and Albuminuria

Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients With Hypertension

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Correspondence with the SEC

Letter from the SEC

SEC STAFF LETTER